In a transaction that embodied many underlying trends in the healthcare sector, ResMed Inc. (NYSE: RMD), a provider of medical devices that treat patients with sleep disorders, bought Brightree, a developer of cloud-based software to improve clinical and business performance for post-acute-care (PAC) providers, for $800 million. The purchase underscores the ongoing shift in the U.S. healthcare system from a fee-for-service model to a fee-for-value model and the need for players across the healthcare continuum to use informatics and data analytics as tools to share information and deliver care more efficiently.
“Brightree was an important and immediately accretive strategic acquisition for ResMed. It exemplified a double-down on our ongoing investments to leverage connected care and digital health, and to change the basis of competition in our industry,” ResMed CEO Mick Farrell told Mergers & Acquisitions in a March 2017 interview. “One year from announcing the acquisition, we can reaffirm our goals going in: Brightree represents a big step forward for ResMed, fulfilling our role as the world’s leading tech-driven medical device company, liberating data and unlocking incredible value for our customers.”